Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Common Equity (2016 - 2025)

Mimedx (MDXG) has disclosed Common Equity for 15 consecutive years, with $256.5 million as the latest value for Q4 2025.

  • Quarterly Common Equity rose 32.85% to $256.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $256.5 million through Dec 2025, up 32.85% year-over-year, with the annual reading at $256.5 million for FY2025, 32.85% up from the prior year.
  • Common Equity hit $256.5 million in Q4 2025 for Mimedx, up from $238.9 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $256.5 million in Q4 2025 to a low of -$19.5 million in Q3 2022.
  • Historically, Common Equity has averaged $82.3 million across 5 years, with a median of $706000.0 in 2021.
  • Biggest five-year swings in Common Equity: crashed 22036.59% in 2022 and later skyrocketed 13509.62% in 2024.
  • Year by year, Common Equity stood at $82000.0 in 2021, then plummeted by 22036.59% to -$18.0 million in 2022, then surged by 893.4% to $142.7 million in 2023, then skyrocketed by 35.31% to $193.1 million in 2024, then surged by 32.85% to $256.5 million in 2025.
  • Business Quant data shows Common Equity for MDXG at $256.5 million in Q4 2025, $238.9 million in Q3 2025, and $216.6 million in Q2 2025.